SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

SPY is trending due to futures surging on news of a potential ceasefire in the Middle East and cooling oil prices, driving active community debate between bears expecting a bull trap and bulls celebrating the reversal. Traders are heavily focused on navigating extreme volatility ahead of a packed week featuring major big tech earnings and central bank updates.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors react to new federal executive orders aimed at accelerating U.S. quantum technology leadership and secure data migration. The community is actively debating the stock's long-term potential versus concerns over high cash burn rates, recent insider selling, and the reliability of government-linked catalysts.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is facing a pivotal week as investors await the upcoming FDA Advisory Committee meeting to review the clinical data for its Duchenne muscular dystrophy treatment, Deramiocel. The community is focused on the potential for a dual-label approval and the implications of a high short interest, with many anticipating significant volatility following the release of the briefing documents.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a negative CHMP opinion for Yartemlea in Europe, fueling volatility while the company prepares for an appeal and re-examination. The community is actively debating the impact of this regulatory setback against the backdrop of US-based commercial momentum, recent insider debt repurchases, and the upcoming activation of a permanent J-code for reimbursement.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQ is facing intense short-term volatility as bearish options activity and merger arbitrage concerns weigh on the stock, fueling community debates over whether the recent pullback represents a genuine capitulation or a prime accumulation opportunity. While traders remain focused on short-term price levels and technical support, long-term investors are highlighting the company's expanding manufacturing ecosystem, government partnerships, and the broader potential of its trapped-ion technology as key catalysts for future growth.

Amkor Technology, Inc. engages in the provision of outsourced semiconductor packaging and test services. Its services include design, package characterization, test, and wafer bumping services. The company was founded in 1968 and is headquartered in Tempe, AZ.

AMKOR Technology Inc.

AMKR is seeing heightened investor interest ahead of its earnings report, with the community closely tracking the stock's role in the AI hardware supply chain and advanced semiconductor packaging. Bulls are highlighting recent partnerships with major chip developers as a long-term growth catalyst, while others are monitoring volatility and potential institutional hedging activity.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: QNX, Secure Communications, and Licensing. The QNX segment includes development of safe and reliable software for embedded systems across technology-driven industries. The Secure Communications segment delivers operational resiliency with a government-grade portfolio of secure, certified solutions for mobile fortification, critical communications and crisis management. The Licensing segment focuses on management and monetization of the firm's global patent portfolio. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is trending as investors focus on the expansion of its QNX software platform into the high-growth fields of physical AI, robotics, and next-generation software-defined vehicles. The community remains highly bullish on the company's long-term potential, actively discussing the imminent release of the 'Alloy Kore' platform and the broader strategic value of its safety-certified foundational technology amid industry partnerships with major chipmakers and automotive OEMs.

Venture Global, Inc. engages in the provision of United States liquefied natural gas sourced from resource rich North American natural gas basins. It operates through the following segments: Calcasieu Project, Plaquemines Project, CP2 Project, and Sales and shipping. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is surging as investors react to a significant jump in liquefaction fees and strong Q2 earnings that underscore the company's ability to capitalize on the elevated global LNG spot prices resulting from ongoing Middle East shipping disruptions. The community is focused on the stock's role as a critical energy infrastructure provider, with bullish sentiment fueled by supply constraints in the Strait of Hormuz and anticipation for capacity expansion projects coming online.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is experiencing significant market volatility driven by a $53 million private placement that has sparked intense debate over potential dilution versus growth prospects. The community is deeply divided, with many traders monitoring for short squeeze potential amid low float conditions, while others express caution regarding the long-term fundamentals and the risk of a sharp reversal.

SK hynix, Inc. engages in the manufacture and sale of semiconductor products. Its products include dynamic random access memory, flash memory, complementary metal oxide semiconductor image sensor, and others. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is experiencing significant volatility and trading volume as investors react to a massive 500 billion dollar AI partnership with Nvidia, even as community sentiment remains divided over the sustainability of its current price and the ADR's premium relative to its Korea-listed shares. Market participants are intensely focused on upcoming earnings and the potential for shifts in global AI infrastructure capital expenditure to sustain the semiconductor demand cycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's in Store for Core Laboratories Stock in Q2 Earnings?

CLB's Q2 may reflect resilient international activity and tariff insulation, but weaker reservoir description results and higher costs could weigh.

Earnings Preview: Core Laboratories (CLB) Q2 Earnings Expected to Decline

Core Laboratories (CLB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Are Options Traders Betting on a Big Move in Core Laboratory Stock?

Investors need to pay close attention to CLB stock based on the movements in the options market lately.

Core Stock Down 39% in 6 Months: Should You Hold or Sell Now?

CLB struggles with ongoing headwinds from lower completion activity, operational disruptions, inflationary costs, weaker margins and projected earnings decline in 2026.

Liberty Energy Stock Surges 96% in a Year: Is There More Upside Ahead?

LBRT stock surges 96% in a year, but can demand for premium services, power expansion and technology innovation drive further gains amid key risks?

Gulfport Energy and Mobility Global Set to Join S&P SmallCap 600

Gulfport Energy and Mobility Global Set to Join S&P SmallCap 600 Gulfport Energy and Mobility Global Set to Join S&P SmallCap 600 PR Newswire NEW YORK, June 26, 2026 NEW YORK, June 26, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600: Gulfport...

Core Lab Stock Plunges 18% in 3 Months: Time to Hold or Fold?

CLB faces persistent geopolitical uncertainty, weaker laboratory activity, cost inflation and delayed shipments, limiting visibility into a stronger recovery.

Core Laboratories (CLB) Down 4.9% Since Last Earnings Report: Can It Rebound?

Core Laboratories (CLB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Implied Volatility Surging for Core Laboratories Stock Options

Monday's ETF Movers: IEZ, PBW

In trading on Monday, the iShares U.S. Oil Equipment & Services ETF is outperforming other ETFs, up about 3.2% on the day. Components of that ETF showing particular strength include shares of Nabors...

Core Laboratories, Inc. provides proprietary and patented reservoir description and production enhancement services. It operates through the Reservoir Description and Production Enhancement segments. The Reservoir Description segment engages in petroleum reservoir analysis for energy. The Production Enhancement segment includes services and manufactured products associated with reservoir well completions, perforations, stimulation, production and well abandonment. The company was founded in 1936 and is headquartered in Houston, TX.

Core Laboratories Inc

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$11.67
Prev Close	$11.80
Open	$11.94
Dividend Yield	0.25%
50-Day Moving Average	$12.39
Beta	1.12
Avg. Volume	794,316.84
PE Ratio	17.36

52-Week High	$20.36
52-Week Low	$9.72
Market Capitalization	$537.95M
EPS (Annual)	$0.639
Price to Book	2.00
Revenue Per Employee	$159,551.52

Feed

News

Sentiment

Earnings

Fundamentals

Info

CLBCore Laboratories N.V.

Latest CLB News